南華早報Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
作者 Shi Huang
文章摘要
南華早報 · 文章頁摘要The treatment is already approved for some indications in China and could mark a shift in how cancers are treated, researchers say.
原站閱讀
全文請至原站閱讀。